The proof is in the pipeline. See how far we’ve come already.

filter by:
  • All
  • Cardiology/Metabolic
  • CNS/Neurology
  • Dermatology
  • Hematology/Oncology
  • Immunology/IO
  • Ophthalmology
  • Other
  • All
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2

With a high-scale strategy for discovering novel medicines, we require a similarly innovative business model to ensure our lead, clinical-stage programs advance through clinical trials and get to patients as efficiently as possible. That is why we are spinning out new companies to advance our lead assets. To learn more about the first venture company to take our Neurofibromatosis Type 2 asset forward, read the blog introducing CereXis and its CEO Dr. Mani Mohindru.

Discovery Partnership

We can broadly model biology across therapeutic areas to derive novel insights and discover first-in-class treatments. We partner with pharmaceutical companies to identify and develop novel medicines for indications with high unmet need.